These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27216427)

  • 1. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
    Messori A
    Clin Drug Investig; 2016 Aug; 36(8):599-603. PubMed ID: 27216427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolocumab and alirocumab: exploring original procurement models to manage the reimbursement of these innovative treatments.
    Messori A
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):771-4. PubMed ID: 27117037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab.
    Hernandez I
    JAMA Intern Med; 2017 Sep; 177(9):1388-1390. PubMed ID: 28783812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.
    Messori A
    Sci Pharm; 2016; 84(1):73-9. PubMed ID: 27110499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
    Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
    Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
    Ha SY; Kang DW; Jung HI; Lee EK; Park MH
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
    Pauly MV
    Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
    Schiff L
    Clin Ther; 2015 May; 37(5):1092-112. PubMed ID: 25850880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The End of the International Reference Pricing System?
    Persson U; Jönsson B
    Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 Inhibitors: Economics and Policy.
    Hlatky MA; Kazi DS
    J Am Coll Cardiol; 2017 Nov; 70(21):2677-2687. PubMed ID: 29169476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.